South Korea

Latest Headlines

Latest Headlines

China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi

Shanghai-based ZAI Lab has in-licensed China rights for HM61713, a tumor-targeting EGFR tyrosine kinase inhibitor from South Korea's Hanmi, which has racked up an impressive string of license deals this year.

Samsung Bioepis biosimilar gets 'positive opinion' from European agency

South Korea's Samsung Bioepis said its biosimilar drug Benepali, used in the treatment of rheumatoid arthritis and other autoimmune diseases, has received a "positive opinion" from the European Medicines Agency's Committee for Medicinal Products for Human Use.

Indonesia's Kalbe and South Korea's Genexine link up for biomedical work

Indonesia's Kalbe Farma has signed a deal with South Korea's Genexine in which it will invest $9.1 million to develop biopharmaceutical products and create an R&D laboratory in Indonesia to research the hormone erythropoietin, which helps produce red blood cells, according to a report by the Nikkei Asian Review.

Potential $125M biologics deal between South Korea's Genexine and China's Tasly inked

South Korea biotech Genexine has put together a second deal in Asia this month, licensing out 5 protein therapies with a subsidiary of China's Tasly Pharmaceutical worth a potential $125 million and which follows a joint venture plan with Indonesia's Kalbe Farma.

HK-listed 3SBio inks oncology antibody drug deal with South Korea's Alteogen

China biotech 3SBio said it has signed an exclusive licensing deal with South Korea's Alteogen for the development, manufacturing and marketing of ALT-P7, an antibody-drug conjugate used in cancer treatments, keeping it on a steady deal streak since a public relisting this summer.

South Korea's SK Chemicals says flu vaccine sales pass 1M doses in 2 weeks

South Korea's SK Chemicals said domestic sales of the country's first cell-culture flu vaccine, SKYCellflu, passed 1 million doses within two weeks of launch. Plans for sales abroad are also in the cards.

Lee family victory in Samsung shareholder challenge sets stage for biologics ramp up

A thwarted challenge from an activist investor to block the $8 billion merger of Samsung C&T and Cheil Industries last week has set the stage for family-controlled Samsung Electronics and related units to focus on boosting already rapid growth at Samsung BioLogics and Samsung Bioepis, the Korea Herald reports.

Watch out AbbVie, Samsung Bioepis does fine with Humira biosimilar in PhIII

South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.

S. Korea sees extra $9B in spending to handle MERS outbreak

South Korea has set out plans to spend an additional KRW10 trillion ($9 billion) to manage the outbreak of Middle East respiratory syndrome that has afflicted 179 and caused 27 deaths since May, news reports said.

South Korea biopharma IPOs highlight demand

Two South Korean firms, Corestem and Kyongbo Pharmaceutical, this week showed solid investor demand for biopharma stocks in the country.